<DOC>
	<DOCNO>NCT02325791</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , pharmacokinetics ( PK ) , immunogenicity REGN2222 infant bear 35 wGA ( week gestational age ) , 6 month age time enrollment respective geographic location . In order optimize potential benefit vulnerable population , conduct study RSV season use dose regimen expect effective .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety REGN2222 , Prevention Medically Attended RSV ( Respiratory Syncytial Virus ) Infection Preterm Infants</brief_title>
	<detailed_description>This study occur two part : Part A Part B . The status Part A 'Complete ' . The status Part B 'Active , recruit . ' Part A study open-label , PK evaluation intramuscular ( IM ) administer REGN2222 preterm infant palivizumab recommend enable selection dose regimen Part B . Part B study randomize , double-blind , placebo-controlled , design evaluate efficacy , safety , serum concentration immunogenicity IM administration REGN2222 preterm infant palivizumab recommend . The total duration Part B 265 day ( include 28-day screening period , 57-day treatment period 180-day follow-up period ) . Up 1515 subject plan include Part B study . Participants randomly assign 1 3 different group , 505 infant ; 1 group get 1 dose REGN2222 1 dose placebo , second group receive 2 dos REGN2222 , third group receive 2 dos placebo . There separate genetic test sub study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>1 . Preterm , otherwise healthy male female infant ≤6 month age time first dose ( i.e. , infant must treat 6 month birthday ) 2 . Gestational age ≤35 week birth 3 . Parent ( ) legal guardian ( ) infant able understand study requirement willing provide inform consent 1 . Eligible recommend receive palivizumab per AAP local guideline , standard practice , healthcare provider 2 . History CLD define requirement supplemental oxygen 28 day birth 3 . Known hemodynamically significant congenital heart disease 4 . Known immunodeficiency , neuromuscular disease , congenital abnormality airway 5 . Known renal hepatic dysfunction 6 . Major congenital malformation , include congenital cleft palate , cytogenetic abnormality , serious chronic disorder 7 . Known suspected impairment immunological function autoimmune diseases 8 . History anaphylaxis 9 . Previously receive palivizumab investigational RSV prophylaxis vaccine product 10 . Previous reaction IV immunoglobulin , blood product foreign protein , include vaccine monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>